Inventor · disambiguated record
Andrea Hägebarth
Also filed as: HAEGEBARTH ANDREA · HÄGEBARTH ANDREA
17 granted patents·10 pending applications·45 citations·filing 2011–2016
89Inventor score
Top patents by PatentIndex Score
27 records- 0190US8987273B2Substituted imidazo[1,2-B]pyridazinesREHWINKEL HARTMUT·Filed 2011·Granted Mar 24, 2015·28 cites·18 claims
- 0280US9382255B2Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitorsBayer Pharma AG·Filed 2013·Granted Jul 5, 2016·3 cites·9 claims
- 0375US9409889B2Amino-substituted imidazopyridazinesBayer Pharma AG·Filed 2013·Granted Aug 9, 2016·3 cites·9 claims
- 0473US8975265B2Substituted imidazo[1,2-a]pyrimidines and —pyridinesINCE STUART·Filed 2011·Granted Mar 10, 2015·3 cites·10 claims
- 0572US9540392B2ThienopyrimidinesBayer Pharma AG·Filed 2013·Granted Jan 10, 2017·2 cites·10 claims
- 0672US9370517B2Substituted pyrazolopyrimidines as Akt kinase inhibitorsBAYER IP GMBH·Filed 2013·Granted Jun 21, 2016·2 cites·8 claims
- 0770US8895549B2Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisSCOTT WILLIAM JOHNSTON·Filed 2011·Granted Nov 25, 2014·2 cites·15 claims
- 0867US9206185B2Imidazopyridazines as Akt kinase inhibitorsBärfacker Lars·Filed 2012·Granted Dec 8, 2015·2 cites·39 claims
- 0953US9902727B2Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisBAYER IP GMBH·Filed 2014·Granted Feb 27, 2018·0 cites·15 claims
- 1052US2016159816A1Substituted thienopyrimidines and pharmaceutical use thereofBayer Pharma AG·Filed 2014·Application pending·0 cites
- 1150US2015252047A1Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseasesBayer Pharma AG·Filed 2013·Application pending·0 cites
- 1244US8987286B2Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathwayREHWINKEL HARTMUT·Filed 2011·Granted Mar 24, 2015·0 cites·11 claims
- 1343US9783543B2AminoimidazopyridazinesBayer Pharma AG·Filed 2013·Granted Oct 10, 2017·0 cites·8 claims
- 1443US9745304B2Amidoimidazopyridazines as MKNK-1 kinase inhibitorsBayer Pharma AG·Filed 2014·Granted Aug 29, 2017·0 cites·9 claims
- 1543US9604989B2Imidazopyridazines as Akt kinase inhibitorsBAYER IP GMBH·Filed 2015·Granted Mar 28, 2017·0 cites·6 claims
- 1642US10130633B2CompoundsBayer Pharma AG·Filed 2014·Granted Nov 20, 2018·0 cites·17 claims
- 1742US9777004B2Amino-substituted imidazopyridazinesBAYER IP GMBH·Filed 2013·Granted Oct 3, 2017·0 cites·9 claims
- 1842US9260435B2Substituted imidazopyrazines as Akt kinase inhibitorsBAYER IP GMBH·Filed 2013·Granted Feb 16, 2016·0 cites·8 claims
- 1942US2015218173A1Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disordersBayer Pharma AG·Filed 2013·Application pending·0 cites
- 2042US2016052898A1Novel compoundsBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2141US9643974B2Amino-substituted imidazopyridazinesBAYER IP GMBH·Filed 2012·Granted May 9, 2017·0 cites·9 claims
- 2233US2018044306A11,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitors of the wnt signalling pathwayBayer Pharma AG·Filed 2016·Application pending·0 cites
- 2333US2018042931A1N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathwaysBayer Pharma AG·Filed 2016·Application pending·0 cites
- 2433US2018028507A13-carbamoylphenyl-4-carboxamide and isophtalamide derivatives as inhibitors of the wnt signalling pathwayBayer Pharma AG·Filed 2016·Application pending·0 cites
- 2531US2013184273A1Bicyclic pyrimidinesINCE STUART·Filed 2011·Application pending·0 cites
- 2631US2017107212A1Novel compoundsBayer Pharma AG·Filed 2015·Application pending·0 cites
- 2731US2017114070A1Inhibitors of the wnt signalling pathwaysBayer Pharma AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrea Hägebarth files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →